FGL1 and neoplasm: Lieping Chen et al. reported in Cell [19] that FGL1 was a major immune inhibitory ligand of LAG-3 and blockade of the FGL1-LAG-3 interaction could enhance anti-tumor immunity, suggesting that FGL1-LAG-3 pathway was an important immune evasion mechanism and a potential target for immunotherapy.